Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.55 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818801 | 1.00 | ALDH1A1 (0.65) | ALDH1A1KDM4EPTGER4TEAD1PHGDH | |
| SCHEMBL2032041 | 1.00 | ALDH1A1 (0.65) | ALDH1A1KDM4EPTGER4TEAD1PHGDH | |
| SCHEMBL20791371 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4EPTGER4TEAD1SMN1; SMN2 | |
| SCHEMBL28107119 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4EPTGER4TEAD1SMN1; SMN2 | |
| SCHEMBL1816846 | 0.86 | KDM4E (0.52) | ALDH1A1KDM4EPTGER4SMN1; SMN2HRH3 | |
| SCHEMBL2027416 | 0.86 | KDM4E (0.52) | ALDH1A1KDM4EPTGER4SMN1; SMN2HRH3 | |
| SCHEMBL17320112 | 0.84 | ALDH1A1 (0.67) | ALDH1A1KDM4EPTGER4SMN1; SMN2SIGMAR1 | |
| SCHEMBL1817113 | 0.84 | ALDH1A1 (0.67) | ALDH1A1KDM4EPTGER4SMN1; SMN2SIGMAR1 | |
| SCHEMBL1009407 | 0.84 | ALDH1A1 (0.67) | ALDH1A1KDM4EPTGER4SMN1; SMN2SIGMAR1 | |
| SCHEMBL1819133 | 0.84 | IDO1 (0.53) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638871-B | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonist | 罗达制药生物技术有限责任公司 | 2024-08-30 | — | — | CN | disclosed |
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-08-08 | — | — | US | disclosed |
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-08-08 | — | — | US | disclosed |
| EP-3820842-B1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech Srl (IT) | 2023-03-29 | — | — | EP | disclosed |
| EP-3820842-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech S.r.l. (IT) | 2021-05-19 | — | — | EP | disclosed |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-05-06 | — | — | US | disclosed |
| CN-112638871-A | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020012305-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | ALDH1A1 532/4885KDM4E 1538/4885PTGER4 1/4885 |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | PTGER4, PTGER1, PTGER2 | ALDH1A1 532/4885KDM4E 1538/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.